로딩 중…
StockDiggingStockDigging

Boston Scientific Corporation

BSX· NYSE
$45.30+0.77%
2026-06-18

Price Chart

Boston Scientific Corporation-55.32%

Financials

※ FY = Fiscal Year

Investment Metrics(as of 2026-06-18)

MetricValue
Size
Market Cap$67.32B
Revenue$20.61B
Net Income$3.55B
Total Assets$44.35B
Net Assets$25.86B
Employees59,000
Value
P/E18.95x
P/B2.60x
PEG0.19x
P/S3.27x
EV/EBITDA16.13x
FCF Yield5.11%
Profitability
ROE13.74%
ROA8.01%
Op. Margin20.12%
Revenue Growth11.58%
Earnings Growth98.37%
Financial Health
Debt Ratio70.55%
Total Debt$11.03B
FCF$3.44B
Cash$1.52B
Current Ratio1.90x
Net Debt/EBITDA2.00x
Performance
1Y Return-55.32%
1M Return-20.27%
From 52W High-58.63%
1Y MDD-58.43%
Trading
Volume21,166,552 shares
Trading Value$954M
Per Share
EPS$1.95
BPS$16.34

Company Info

CEO Mr. Michael F. Mahoney
Employees 59,000
HQ Marlborough, United States

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.